Noxilizer partner with Lead Candidate to grow senior leadership team

Lead Candidate, a specialist talent consultancy serving the pharma and bio outsourcing space, has partnered with Noxilizer, a leading provider of ultra-low temperature sterilization technology for the pharma, biotech, and medical device industries.

This collaboration follows Noxilizer’s recent announcement of a $30 million growth capital investment, led by healthcare-focused growth equity firm, NewVale Capital.

To meet rising demands for a safer alternative solution to traditional sterilization methods, Noxilizer is entering a significant phase of expansion. As part of this growth journey, Lead Candidate will support the appointment of three senior leadership positions.

Andrew Mears, CEO of Lead Candidate, commented: “We’re proud to be partnering with Noxilizer at such an exciting time in the journey. With the backing of NewVale Capital and a clear roadmap for growth, Noxilizer is extremely well positioned to make a real impact in the market. Bringing in the right people now will be critical in delivering the strategic growth plan, and it’s a real privilege for Lead Candidate to play a part in that.”

Christopher Thatcher, CEO & President at Noxilizer, said: “Partnering with Lead Candidate ensures we attract the right leadership to support Noxilizer’s next stage of growth. Their deep industry knowledge and proven track record in executive search makes them a valuable partner as we lay the foundations for Noxilizer’s next chapter.”

For more information about the open opportunities to join the Noxilizer team, please reach out to Andrew Mears or Brandon Miller directly.

About Lead Candidate

Lead Candidate is a talent consultancy partner, specializing in supporting businesses in the global pharma and bio outsourcing space. The company is dedicated to helping CDMOs, CROs, and pharma services organisations, achieve their goals through strategic growth. For additional information, please visit www.leadcandidate.com.

About Noxilizer

Noxilizer provides ultra-low temperature nitrogen dioxide (NO₂) terminal sterilization for the pharmaceutical, biotechnology, and medical device industries. With FDA approvals and clearance, EMA authorization, and adoption by leading global manufacturers, Noxilizer’s NO₂ sterilization is a safe, efficient, and scalable alternative to existing methods. The company offers R&D studies, packaging and design consulting, validation and customer and technical support in addition to its proprietary sterilization equipment and consumables. Noxilizer is headquartered in Hanover, Maryland. For more information, please visit: www.noxilizer.com.